TP53 and melanoma: In melanoma, reducing levels of the p53 protein contributes to boost aggressiveness and refractoriness to therapy; inactivation of p53 can be due to mutations of p14CDKN2A or to increased expression of MDM2 or, alternatively, to silencing of the TP53 gene (by epigenetic mechanisms or, to a less extent, sequence mutations) (12, 15).